Webinar will highlight the company’s progress in leveraging artificial intelligence to develop medicines that address fundamental mechanisms of mitochondrial biology and protein homeostasis.
Boston, MA – July 25, 2024 – BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced a virtual fireside chat to be held Tuesday, July 30, 2024, from 11:00am – 12:00pm EDT. The event, “How will AI/Machine Learning & High-Speed Computing Impact Drug Discovery and Development?” will feature distinguished speakers from BPGbio and several of its collaborating institutions. Speakers will discuss the power of the company’s NAi Interrogative Biology® platform, and BPGbio’s initial successes in leveraging its AI capabilities and large clinically annotated biobank to develop drugs for oncology, rare disease, and neurology applications.
The event brings together the world’s top experts in brain diseases and pancreatic cancer, as well as the U.S. government’s top expert who runs the world’s fastest supercomputer at Oak Ridge National Laboratory to discuss BPGbio’s revolutionary innovations currently being validated in human clinical trials. Kimberly Minarovich, Managing Director of Argot Partners, will moderate the event and introduce the challenges that society faces in improving human health in the face of rising incidence of age-related cancers and neurodegeneration.
“BPGbio has reached an inflection point in our company’s history as we build on our early scientific innovations, pursue later stage trials of our revolutionary AI-designed therapeutics portfolio, and begin a multiyear transition into a commercial enterprise,” said Niven R. Narain, President and CEO of BPGbio. “With several successful clinical trials under our belt and no clinical trial failures, we have proven that our NAi Interrogative Biology platform and unique approach to AI-powered biology can underpin the development of a robust therapeutics portfolio.”
Event speakers will include:
Governor’s Chair and Director, University of Tennessee; Director, Center for Molecular Biophysics at Oak Ridge National Laboratory.
His research interests include high-performance computer simulation of biological macromolecules, supercomputing, bioenergy, environmental biogeochemistry, drug and vaccine design, and biological neutron scattering. He has published over 400 peer-reviewed articles.
Nash Family Professor of Neuroscience; Director, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai.
He is an accomplished neuroscientist aiming to develop improved treatments. He has held prestigious academic positions at Yale University and the University of Texas Southwestern Medical Center and is a member of the Institute of Medicine and a Fellow of the American Academy of Arts and Sciences.
Chief, Division of Cancer Medicine, Banner MD Anderson Cancer Center.
He specializes in gastrointestinal cancers, particularly pancreatic cancer, and has been actively involved in clinical trials. He completed his medical and PhD degrees at Kasturba Medical College and his residency and fellowship at the Cleveland Clinic Foundation and Mayo Clinic, respectively.
Chairman, President & CEO of BPGbio.
He is a pioneer in AI-driven drug discovery, with over 400 patents. He developed the NAi Interrogative Biology® platform that has unraveled actionable disease insight leading to both de novo and repurposed development of a robust pipeline of products in oncology, metabolic, rare, and CNS diseases, namely BPM 31510 currently in Phase 2 trials for cancer. These discoveries are covered by over 400 issued and pending US and international patents.
Board Member, BPGbio.
He is a serial entrepreneur who has led six companies as CEO across a range of industries including automotive, energy, technology, and most recently a multi-$B healthcare diagnostics company. Earlier in his career, Mr. Elliott participated in development and turnaround of multiple venture and PE-backed companies, resulting in positive investor returns. Mr. Elliott is also serving as Managing Director at Phoenix Genesis, a private investment fund.
Webinar Details
The webinar is free and open to the public. Register here: https://bit.ly/bpgbio.
About BPGbio Inc.
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease, and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
